Previous Close | 3.0400 |
Open | 3.0000 |
Bid | 2.9800 x 1100 |
Ask | 3.0700 x 1000 |
Day's Range | 2.8700 - 3.0913 |
52 Week Range | 1.1300 - 8.5800 |
Volume | |
Avg. Volume | 960,962 |
Market Cap | 126.73M |
Beta (5Y Monthly) | 1.52 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6740 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.67 |
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced company highlights and financial results for the second quarter ended June 30, 2022.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and one-on-one meetings at the William Blair Biotech Focus Conference 2022, which is taking place at The St. Regis New York on July 12 – 13, 2022.
A look at the shareholders of Cardiff Oncology, Inc. ( NASDAQ:CRDF ) can tell us which group is most powerful. Insiders...